Data further reinforces the value of Foundation Medicine’s proprietary homologous recombination deficiency (HRD) signature

Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, today announced that the company and its collaborators will present 14 abstracts at the 2022 European Society for Medical Oncology Congress being held virtually and in person in Paris from September 9-13, 2022.

Highlights from the presentations include:

• Two studies leveraging Foundation Medicine’s novel homologous recombination deficiency signature (HRDsig) to explore whether this biomarker is associated with FOLFIRINOX benefit in patients with metastatic pancreatic cancer via the Flatiron Health-Foundation Medicine Clinico-Genomic Database (CGDB), and to understand the prevalence of HRDsig positivity in non-small cell lung cancer using FoundationOne®CDx.
  
  
  
  
• A real-world analysis of 447 men in the CGDB with de novo metastatic prostate cancer treated in standard of care settings, found that the subgroup with SPOP mutations had much more favorable time to castration resistance and overall survival if treated with second generation hormonal agents versus docetaxel. Another study using Foundation Medicine’s tissue-based comprehensive genomic profiling (CGP) test found that SPOP mutations occur in a moderate number of Clinically Advanced Prostate Cancer (CAPC) cases and are associated with lower frequencies of TMPRSS2: ERG fusions, AR amplifications, cell cycle genomic alterations (GA) and MTOR pathway GA and higher frequencies of immunotherapy drug efficacy biomarkers including microsatellite instability-high (MSI-H), tumor mutational burden high (TMB-H) and PD-L1 status.
  
  
  
  
• A large-scale analysis of lung cancer cases, sequenced using FoundationOne CDx, to identify genomic alterations associated with loco-regional lesions, extracranial metastases and brain metastases to determine their functional roles and downstream pathways, providing a foundation for the development of RICTOR-targeted therapeutic strategies for the treatment and/or prevention of lung cancer brain metastases.
  
  

• A characterization of the genomic landscapes of TMB-H versus TMB-low (TMB-L) in patients with intrahepatic cholangiocarcinomas (iCCA) using FoundationOne CDx. Findings support the clinical development of immunotherapy approaches for the treatment of TMB-H iCCA patients.

“This data demonstrates the power of our tissue- and liquid-based comprehensive genomic profiling tests for enabling critical research on complex genomic signatures and emerging biomarkers,” said Priti Hegde, PhD, Chief Scientific Officer at Foundation Medicine. “We’re proud to be working across the cancer research community to deepen our collective understanding of cancer biology and ultimately support better care for patients in the future.”

The following is a list of abstracts that will be presented at the meeting. To access all abstracts being presented at ESMO, please visit: https://oncologypro.esmo.org/meeting-resources/esmo-congress

Follow Foundation Medicine on Twitter and LinkedIn for more updates from #ESMO22 and visit us in person at booth #306.

*May include previous versions of Foundation Medicine’s assays

About Foundation Medicine: Your Essential Partner in Cancer Care

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on Twitter and LinkedIn.

About FoundationOne®CDx

FoundationOne CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. FoundationOne CDx is for prescription use only and is intended as a companion diagnostic to identify patients who may benefit from treatment with certain targeted therapies in accordance with their approved therapeutic product labeling. Additionally, FoundationOne CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For a full list of targeted therapies for which FoundationOne CDx is indicated as a companion diagnostic, please visit www.F1CDxLabel.com.

About FoundationOne®Liquid CDx

FoundationOne Liquid CDx is a qualitative next generation sequencing based in vitro diagnostic test for prescription use only that uses targeted high throughput hybridization-based capture technology to analyze 324 genes utilizing circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of advanced cancer patients. The test is FDA-approved to report short variants in over 300 genes and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.

Foundation Medicine^®, FoundationOne^® and FoundationCore^® are a registered trademark of Foundation Medicine, Inc.

Source: Foundation Medicine

View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005316/en/